|
rs121913377
|
|
Neoplasm Metastasis
|
|
0.100 |
GeneticVariation
|
BEFREE |
Thirty-three samples (7 of 25 primaries, 15 of 25 regional metastases, 5 of 25 nodal metastases, and 6 of 10 distant metastases) harbored the V599E B-RAF mutation (39%), 12 contained a Q61R N-RAS mutation and 5 a Q61K N-RAS mutation.
|
14695143 |
2003 |
|
rs121913377
|
|
Neoplasm Metastasis
|
|
0.100 |
GeneticVariation
|
BEFREE |
There were significant differences in clinicopathological parameters, such as extrathyroidal extension (P=0.031), nodal metastasis (P=0.021) and BRAF(V600E) mutation (P=0.039), between NF-κB-positive and negative PTCs.
|
23528368 |
2013 |
|
rs121913377
|
|
Neoplasm Metastasis
|
|
0.100 |
GeneticVariation
|
BEFREE |
This metastasis was found to have BRAF V600E mutation.
|
29405341 |
2018 |
|
rs121913377
|
|
Neoplasm Metastasis
|
|
0.100 |
GeneticVariation
|
BEFREE |
Patients with PTC harboring the BRAF(V600E) mutation seem to display a more aggressive clinical behavior, but little is known about the role of this mutation in crucial processes in the tumor microenvironment, such as tumor adhesion, migration, invasion, and metastasis.
|
21447745 |
2011 |
|
rs121913377
|
|
Neoplasm Metastasis
|
|
0.100 |
GeneticVariation
|
BEFREE |
All patients with lateral cervical node metastasis (n=9), and all but one tumor with extrathyroidal extension (n=17/18) showed BRAF(V600E) mutation.
|
22918165 |
2013 |
|
rs121913377
|
|
Neoplasm Metastasis
|
|
0.100 |
GeneticVariation
|
BEFREE |
Together, these results suggest that targeting mutant (V600E)B-Raf reduces melanoma cell extravasation by decreasing IL-8 production and interrupting ICAM-1-beta2 integrin binding of melanoma cells to the endothelium mediated by PMNs in the microcirculation, which provides a rationale and mechanistic basis for targeting mutant (V600E)B-Raf to inhibit melanoma extravasation and subsequent metastasis development.
|
17575149 |
2007 |
|
rs121913377
|
|
Neoplasm Metastasis
|
|
0.100 |
GeneticVariation
|
BEFREE |
The prevalence of BRAF(V600E) mutation of PTMCs with high aggressiveness (advanced disease stages, extrathyroidal extension, and nodal metastasis) was significantly higher (p < 0.05) than that of PTMCs without aggressive behavior.
|
19034577 |
2009 |
|
rs121913377
|
|
Neoplasm Metastasis
|
|
0.100 |
GeneticVariation
|
BEFREE |
On univariate analysis, the BRAF(V600E) mutation was associated with extrathyroidal extension (P = .009) and variants of PTC (P = .019), but a high-risk Metastasis, Patient Age, Completeness of resection, local Invasion and Tumor Size (MACIS) score (≥ 6) (P = .146) and lymph node metastasis (P = .628) were not significantly associated with the BRAF(V600E) mutation.
|
21803329 |
2012 |
|
rs121913377
|
|
Neoplasm Metastasis
|
|
0.100 |
GeneticVariation
|
BEFREE |
After controlling for the effect of MS status, there was no correlation of RNF43 frameshift mutation with distant metastasis (OR = 1.57 [0.75, 3.28]) and advanced TNM stages (OR = 0.98 [0.58, 1.67]), but RNF43 frameshift mutations still occur more frequently in right colon (OR = 2.58 [1.49, 4.47]) and with BRAF V600E mutation (OR = 1.94 [1.22, 3.10]).
|
31122752 |
2019 |
|
rs121913377
|
|
Neoplasm Metastasis
|
|
0.100 |
GeneticVariation
|
BEFREE |
In this study, the occurrence and percentage of the BRAF V600E mutated allele was not preferentially associated with the development of metastases and the average mutated allele percentage decreased as the tumor progresses from the primary site to the lymph node metastatic sites.
|
23533235 |
2013 |
|
rs121913377
|
|
Neoplasm Metastasis
|
|
0.100 |
GeneticVariation
|
BEFREE |
Overall median survival time (MST), stratified for variables, including BRAF V600E mutation and eligibility for treatments with new immunotherapy drugs, was retrospectively assessed in 41 patients with pelvic melanoma loco regional metastases.
|
29120401 |
2017 |
|
rs121913377
|
|
Neoplasm Metastasis
|
|
0.100 |
GeneticVariation
|
BEFREE |
We successfully treated a BRAF V600E-mutated anaplastic oligoastrocytoma with multiple extraneural metastases with vemurafenib and everolimus.
|
30462564 |
2019 |
|
rs121913377
|
|
Neoplasm Metastasis
|
|
0.100 |
GeneticVariation
|
BEFREE |
Clinically, patients with V600K tumors experience distant metastases sooner and have an increased risk of relapse and shorter survival than patients with V600E tumors.
|
28858076 |
2017 |
|
rs121913377
|
|
Neoplasm Metastasis
|
|
0.100 |
GeneticVariation
|
BEFREE |
We also studied the role of BRAF V600E mutation in a set of melanoma patients who had been investigated for sentinel node metastasis.
|
25442222 |
2015 |
|
rs121913377
|
|
Neoplasm Metastasis
|
|
0.100 |
GeneticVariation
|
BEFREE |
The TERT promoter mutation is an independent predictor for distant metastasis of WDTC, but ALK testing is not useful for clinical decision-making in Korean patients with a high prevalence of the BRAF V600E mutation.
|
26857243 |
2016 |
|
rs121913377
|
|
Neoplasm Metastasis
|
|
0.100 |
GeneticVariation
|
BEFREE |
In the context of metastatic PTC with SCC dedifferentiation, the presence of the identical BRAF (V600E) (c.1799 T > A) mutation in both components might help rule out tumor to tumor metastasis.
|
26521063 |
2016 |
|
rs121913377
|
|
Neoplasm Metastasis
|
|
0.100 |
GeneticVariation
|
BEFREE |
BRAF V600E also predicts poor prognosis in microsatellite stable colorectal cancers and may be a marker of resistance to anti-EGFR therapy in metastatic disease.
|
23650027 |
2013 |
|
rs121913377
|
|
Neoplasm Metastasis
|
|
0.100 |
GeneticVariation
|
BEFREE |
BRAF(V600E) significantly correlated with absence of node metastasis.
|
16452550 |
2006 |
|
rs121913377
|
|
Neoplasm Metastasis
|
|
0.100 |
GeneticVariation
|
BEFREE |
BRAF V600E mutation was identified in 1% of patients only. p53 protein was lowly expressed in TGCT metastases compared to the matched primary tumors.
|
27085458 |
2016 |
|
rs121913377
|
|
Neoplasm Metastasis
|
|
0.100 |
GeneticVariation
|
BEFREE |
BRAF(V600E) mutation is predictive for distant metastasis in papillary thyroid carcinoma but not positively.
|
23981603 |
2013 |
|
rs121913377
|
|
Neoplasm Metastasis
|
|
0.100 |
GeneticVariation
|
BEFREE |
BRAF V600E was associated with advanced TNM (P < 0.001), more distant metastases (P = 0.025), and worse overall survival (OS, P < 0.001; multivariate HR = 4.2, P = 0.004) in colon cancer patients.
|
25367198 |
2014 |
|
rs121913377
|
|
Neoplasm Metastasis
|
|
0.100 |
GeneticVariation
|
BEFREE |
Patients with BRAF(V600E) wild-type primary tumor do not appear to acquire the mutation in their metastases, and BRAF(V600E) is associated with poorer outcomes in metastatic patients.
|
20635392 |
2011 |
|
rs121913377
|
|
Neoplasm Metastasis
|
|
0.100 |
GeneticVariation
|
BEFREE |
However, RAF inhibitors paradoxically accelerate metastasis in RAS-mutant tumors and become ineffective in BRAF(V600E) tumors because of reactivation of downstream mitogen-activated protein kinase (MAPK) signaling.
|
25097033 |
2014 |
|
rs121913377
|
|
Neoplasm Metastasis
|
|
0.100 |
GeneticVariation
|
BEFREE |
NRAS mutant/BRAF wild type metastatic deposits were identified in three patients, with one patient having a BRAF V600E mutant metastatic tumour.
|
31023480 |
2019 |
|
rs121913377
|
|
Neoplasm Metastasis
|
|
0.100 |
GeneticVariation
|
BEFREE |
Therefore, we established a large collection of patient-derived xenografts (PDXs), derived from BRAF(V600E), NRAS(Q61), or BRAF(WT)/NRAS(WT) melanoma metastases prior to treatment with BRAF inhibitor and after resistance had occurred.
|
27320919 |
2016 |